The Osteoarthritis Research Society International's World Congress on Osteoarthritis concluded on April 21, with a clear focus on finding new ways to recognize the disease early and identify and slow progression.
Conferences page on Musculoskeletal Network features reports on the latest in osteoarthritis research, including:
We routinely treat disorders such as rheumatoid arthritis, lupus, scleroderma, and ankylosing spondylitis with immunosuppressive drugs. Yet if infection were known to be the root cause, this course of action would seem counterintuitive, if not potentially dangerous in the short or long run. More »
New biomarkers are identifying an increasing number of women with spondyloarthritis, contrary to the idea that the disease affects mostly men. New research shows that severity and inflammatory lesions differ between the sexes. More »
(AUDIO) A new paradigm in pain research provides simple ways to identify patients with disorders like arthritis or lupus who won't respond to standard treatments. Pain expert Daniel Clauw MD gives the details in this podcast. More »
Reports about lupus from the American College of Rheumatology meeting include news about biomarkers for non-atherosclerotic comorbidities, good results from epratuzumab and hydroxycloroquine, and good news about lymphoma risk. More »
(AUDIO) A well-established program for managing many aspects of chronic disease works well for African American women in an Atlanta lupus clinic. Dr. Christina Drenkard describes the promising outcomesa More »
Doctors at New York's Hospital for Special Surgery have added rituximab and reduced the number of cycles of cyclophosphamide in lupus treatments, leading many patients to forgo steroids and wonder whether they still have the disease. More »
Osteoporosis is a common problem in thalassemics. As the most affected bone is spinal vertebrae, theoretically, it should have the greatest risk of fracture. However, vertebral fracture (VF) in thalassemics was rarely reported. Screening for asympt
Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer. A definitive study comparing the fracture effectiveness and rate of breast cancer for raloxifene and alendronate has not been published. The purpose of this retrospective cohort study was to eval
This is the main page for the National Institute of Arthritis and Musculoskeletal and Skin Diseases, one component of the National Institutes of Health, part of the U.S. Department of Health and Human Services.
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
(AUDIO) Data from a long-term prospective study reveal that, for many older women, the pace of bone mass deterioration takes place on the scale of decades, not single years. Here, the lead author of the study describes how to interpret the results to choose the date for your patient's next bone-density test.